Engineered mesenchymal stem cell-derived extracellular vesicles: A state-of-the-art multifunctional weapon against Alzheimer's disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
With the increase of population aging, the number of Alzheimer's disease (AD) patients is also increasing. According to current estimates, approximately 11% of people over 65 suffer from AD, and that percentage rises to 42% among people over 85. However, no effective treatment capable of decelerating or stopping AD progression is available. Furthermore, AD-targeted drugs composed of synthetic molecules pose concerns regarding biodegradation, clearance, immune response, and neurotoxicity. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are essential intercellular communication mediators holding great promise as AD therapeutics owing to their biocompatibility, versatility, effortless storage, superior safety, and the ability to transport messenger and noncoding RNAs, proteins, lipids, DNAs, and other bioactive compounds derived from cells. The functionalisation and engineering strategies of MSC-EVs are highlighted (e.g. preconditioning, drug loading, surface modification, and artificial EV fabrication), which could improve AD treatment by multiple therapeutic effects, including clearing abnormal protein accumulation and achieving neuroprotection and immunomodulatory effects. Herein, this review summarises state-of-the-art strategies to engineer MSC-EVs, discusses progress in their use as AD therapeutics, presents the perspectives and challenges associated with the related clinical applications, and concludes that engineered MSC-EVs show immense potential in AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00402 · Cited by 5,287
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880 · cited 1×
“Concerning gradient ultracentrifugation, EVs remain in the density equilibrium region and can therefore be separated from impurities [47].”
BackgroundLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666 · cited 1×
“This method is mainly used for gene drugs, which can be transfected into parental cells to overexpress the elements of interest that are subsequently transferred into EVs and function within the target cells [138].”
MethodZhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356
Extracellular vesicles for drug delivery.
Vader, P., Mol, E. A., Pasterkamp, G., & Schiffelers, R. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.006 · Cited by 1,319
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · cited 1×
“The BBB controls the entry of nutrients from the vascular system into the extracellular fluid of the central nervous system (CNS) and limits the passage of harmful exogenous molecules to maintain homeostasis, which severely limits the therapeutic efficacy of drugs against CNS diseases including AD [66].”
BackgroundTherapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712 · cited 1×
“Despite these positive results, negative effects soon occurred, including immunological rejection and cancerous growth due to the size of the cells and the risk of embolism complications [84].”
BackgroundBiomaterials: Foreign Bodies or Tuners for the Immune Response?
Mariani, E., Lisignoli, G., Borzì, R. M., & Pulsatelli, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030636 · Cited by 706
Lee, J.-H., Yang, D.-S., Goulbourne, C. N., Im, E., Stavrides, P., Pensalfini, A., Chan, H., Bouchet-Marquis, C., Bleiwas, C., Berg, M. J., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01084-8 · Cited by 638 · cited 2×
“In addition, autophagy activation was proven to be effective in Aβ plaque scavenging, indicating that autophagy activation represents a promising strategy against AD through clearance of abnormal protein accumulation [105].”
BackgroundReview on Strategies and Technologies for Exosome Isolation and Purification
Chen, J., Li, P., Zhang, T., Xu, Z., Huang, X., Wang, R., & Du, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.811971 · Cited by 585 · cited 1×
“Gradient density ultracentrifugation Density additional steps after centrifugation High purity; Avoiding exosomal damage Labour-intensive; Preliminary preparation; Cumbersome operation [40]”
BackgroundTargeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.02.005 · Cited by 581
Surface Functionalization of Exosomes Using Click Chemistry
Smyth, T., Petrova, K., Payton, N. M., Persaud, I., Redzic, J. S., Graner, M. W., Smith-Jones, P., & Anchordoquy, T. J. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500291r · Cited by 532 · cited 1×
“Chemical approaches include a series of facile click chemistry processes to covalently conjugate EV lipid or protein constructs with different linker groups to achieve various functionalities, as exemplified by thiol-maleimide [146] and azidealkyne cycloadditions [147].”
BackgroundAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · cited 1×
“Exosomes are nanosized EVs with diameters of 40–160 nm that are released by a wide range of cell lines, including those found in the brain, contributing to cell-cell communication [16-19].”
BackgroundMechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
Efficient production and enhanced tumor delivery of engineered extracellular vesicles
Watson, D. C., Bayik, D., Srivatsan, A., Bergamaschi, C., Valentin, A., Niu, G., Bear, J., Monninger, M., Sun, M., Morales-Kastresana, A., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.003 · Cited by 385
Self-citationPerets, N., Betzer, O., Shapira, R., Brenstein, S., Angel, A., Sadan, T., Ashery, U., Popovtzer, R., & Offen, D. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04148 · Cited by 382
Chen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319 · cited 2×
“One such strategy relies on mesenchymal stem cells (MSCs), which exhibit immunoregulatory and tissue regeneration abilities [10, 11].”
BackgroundLiu, S., Fan, M., Xu, J.-X., Yang, L.-J., Qi, C.-C., Xia, Q.-R., & Ge, J.-F. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02393-2 · Cited by 296 · cited 5×
“The underlying therapeutic mechanism of NEP-enhanced hUCMSCs includes the suppression of Aβ accumulation and BACE1 expression, the regeneration of brain-derived BDNF activity, neurogenesis promotion, and increased NEP expression.”
InfluentialChai, Z., Hu, X., Wei, X., Zhan, C., Lu, L., Jiang, K., Su, B., Ruan, H., Ran, D., Fang, R. H., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.027 · Cited by 253
Liu, W.-Z., Ma, Z.-J., Li, J.-R., & Kang, X.-W. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02153-8 · Cited by 252
Shin, J. Y., Park, H. J., Kim, H. N., Oh, S. H., Bae, J.-S., Ha, H.-J., & Lee, P. H. (2014) · Autophagy · doi:10.4161/auto.26508 · Cited by 243
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229 · cited 1×
“As reported, MSC-EVs can penetrate the BBB via their active transport, probably through the traverse of microvascular endothelial cell monolayers of the brain with transiently formed interendothelial gaps [22] and target particular acceptor cells [23, 24].”
Backgroundde Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214 · cited 4×
“Furthermore, MSC-EVs reduce amyloid levels and enhance the expression of the anti-neuronal core antigen of APP/PS1 mice, decreasing the concentrations of Aβ oligomers (AβOs), β-site APP-cleaving enzyme (BACE) and presenilin 1 and promoting the expression of neprilysin (NEP).”
BackgroundInfluentialSodium Oligomannate: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187 · cited 1×
“Sodium oligomannate, which improves the cognitive ability of mild-to-moderate AD patients, was approved in China in 2019 and is the first AD drug targeting the brain-gut axis [8].”
BackgroundCell membrane-derived vesicles for delivery of therapeutic agents
Le, Q.-V., Lee, J., Lee, H., Shim, G., & Oh, Y.-K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.020 · Cited by 181 · cited 1×
“There are still several difficulties in realising the clinical benefits of artificial EVs, including 1) contamination with other organelles and nuclei during the purification process, 2) low coating efficiency due to the limited quality control, and 3) the ratio of cell membranes if fused membranes are used [154].”
BackgroundChen, Y.-A., Lu, C.-H., Ke, C.-C., Chiu, S.-J., Jeng, F.-S., Chang, C.-W., Yang, B.-H., & Liu, R.-S. (2021) · Biomedicines · doi:10.3390/biomedicines9060594 · Cited by 167
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
Baker, S., Polanco, J. C., & Götz, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160371 · Cited by 98 · cited 1×
“Exosomes are nanosized EVs with diameters of 40–160 nm that are released by a wide range of cell lines, including those found in the brain, contributing to cell-cell communication [16-19].”
BackgroundAlzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96
Wang, Q., Cheng, S., Qin, F., Fu, A., & Fu, C. (2021) · RSC Advances · doi:10.1039/d1ra00550b · Cited by 85
Shen, Z., Bao, X., & Wang, R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00314 · Cited by 77 · cited 1×
“As AD progresses, hyperactivation of microglia becomes detrimental and pro-inflammatory, resulting in the M1 phenotype [117].”
Background
Cited by
Amyloid Precursor Protein and Alzheimer’s Disease
Orobets, K. S., & Karamyshev, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914794 · Cited by 141
“…with tyrosine phosphatase-2 (SHP2) deliver SHP2 to the brain, where it induces mitophagy and helps with the clearance of aberrant proteins [123,124]. derived extracellular vesicles (EVs) with tyrosine phosphatase ‐ 2 (SHP2) deliver SHP2 to the brain, where it induces mi ‐ tophagy and helps…”
BackgroundTreatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“Indeed, MSCs can be engineered to release EVs containing siRNA or miRNA against β - amyloid plaques directly (see Figure 1) [182].”
BackgroundEmerging nanotechnology for Alzheimer's disease: From detection to treatment
Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44
Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives
Liu, Z., Liu, M., Xiong, Y., Wang, Y., & Bu, X. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13864 · Cited by 39
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33
“It is posited that transcellular transport of EVs ensues via endocytic uptake by BMECs, an event capable of instigating phenotypic alterations within these cells and modulating the selective permeability of BBB [25, 132, 133].”
Background
Metadata
- Authors
- Yin, T., Liu, Y., Ji, W., Zhuang, J., Chen, X., Gong, B., Chu, J., Liang, W., Gao, J., & Yin, Y.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2023
- Volume
- 13
- Issue
- 4
- Pages
- 1264-1285
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W4320502809
- Cited by
- 98
- References
- 39
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.